A minimal common outcome measure set for COVID-19 clinical research
Clinical research is necessary for an effective response to an emerging infectious disease
outbreak. However, research efforts are often hastily organised and done using various …
outbreak. However, research efforts are often hastily organised and done using various …
Core outcome set for clinical trials of COVID-19 based on traditional Chinese and Western medicine
R Qiu, C Zhao, T Liang, X Hao, Y Huang… - Frontiers in …, 2020 - frontiersin.org
Background Development of a core outcome set (COS) for clinical trials for COVID-19 is urgent
because of the pandemic wreaking havoc worldwide and the heterogeneity of outcomes …
because of the pandemic wreaking havoc worldwide and the heterogeneity of outcomes …
Outcome reporting from protocols of clinical trials of Coronavirus disease 2019 (COVID-19): a review
R Qiu, X Wei, M Zhao, C Zhong, C Zhao, J Hu, M Li… - medRxiv, 2020 - medrxiv.org
Objectives To examine heterogeneity of outcomes in protocols of clinical trials of Coronavirus
Disease 2019 (COVID-19) and to identify outcomes for prioritization in developing a core …
Disease 2019 (COVID-19) and to identify outcomes for prioritization in developing a core …
ResNet18DNN: prediction approach of drug-induced liver injury by deep neural network with ResNet18
Z Chen, Y Jiang, X Zhang, R Zheng, R Qiu… - Briefings in …, 2022 - academic.oup.com
Drug-induced liver injury (DILI) has always been the focus of clinicians and drug researchers.
How to improve the performance of the DILI prediction model to accurately predict liver …
How to improve the performance of the DILI prediction model to accurately predict liver …
Therapeutic effects of wenxin keli in cardiovascular diseases: an experimental and mechanism overview
G Tian, Y Sun, S Liu, C Li, S Chen, R Qiu… - Frontiers in …, 2018 - frontiersin.org
Cardiovascular diseases (CVDs) are the major public health problem and a leading cause of
morbidity and mortality on a global basis. Wenxin Keli (WXKL), a formally classical Chinese …
morbidity and mortality on a global basis. Wenxin Keli (WXKL), a formally classical Chinese …
[HTML][HTML] Comparison of the efficacy of dispensing granules with traditional decoction: a systematic review and meta-analysis
R Qiu, X Zhang, C Zhao, M Li… - Annals of translational …, 2018 - ncbi.nlm.nih.gov
Background Dispensing granules have been developed for about 20 years. However, whether
they are as effective as the traditional decoction kept unclear. This systematic review and …
they are as effective as the traditional decoction kept unclear. This systematic review and …
[PDF][PDF] Protective effects of Liupao tea against high-fat diet/cold exposure-induced irritable bowel syndrome in rats
D Zhou, X Liu, L Lan, W Yu, R Qiu, J Wu, C Teng… - Heliyon, 2023 - cell.com
Liupao tea as a type of dark tea can relieve irritable bowel syndrome by regulating gut
microbiota, but the mechanism has not been fully explained. An ultra-high performance liquid …
microbiota, but the mechanism has not been fully explained. An ultra-high performance liquid …
Study on inoculation fermentation by fungi to improve the taste quality of summer green tea
J Du, X Wu, S Sun, Y Qin, K Liao, X Liu, R Qiu, Z Long… - Food Bioscience, 2023 - Elsevier
Summer green tea (SGT) is not favored by consumers due to its strong bitterness and
astringency. This study aims to improve the taste of SGT using tea-derived fungi isolated from …
astringency. This study aims to improve the taste of SGT using tea-derived fungi isolated from …
Development of a core outcome set for myocardial infarction in clinical trials of traditional Chinese medicine: a study protocol
R Qiu, C Zhong, S Han, T He, Y Huang, M Guan… - BMJ open, 2019 - bmjopen.bmj.com
Introduction Myocardial infarction (MI) is the most dangerous complication in patients with
coronary heart disease. In China, there is an increasing number of randomised controlled …
coronary heart disease. In China, there is an increasing number of randomised controlled …
[HTML][HTML] Development of a core outcome set for the benefits and adverse events of acute heart failure in clinical trials of traditional Chinese medicine and Western …
R Qiu, S Han, X Wei, C Zhong, M Li, J Hu… - Frontiers in …, 2021 - frontiersin.org
Aims: To identify a minimum set of efficacy and adverse events for patients with acute heart
failure (AHF) among different stakeholders in clinical trials of traditional Chinese medicine …
failure (AHF) among different stakeholders in clinical trials of traditional Chinese medicine …